

## **Curis Announces Abstract for CA-4948 Accepted for Presentation at the American Association for Cancer Research Annual Meeting**

LEXINGTON, Mass., March 10, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that an abstract for CA-4948, a small molecule IRAK4 inhibitor, has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which will be held virtually from April 10-15, 2021.

Details of the presentation are as follows:

### **Poster Presentation**

**Title:** Identification of NF-kappaB phospho-p50 as a Potential Predictive Biomarker for IRAK4 inhibitor CA-4948 in Patients with Non-Hodgkin's Lymphoma

**Session Name:** Biomarkers Predictive of Therapeutic Benefit

**Session Date:** Saturday, April 10, 2021

Additional meeting information can be found on the AACR website <https://www.aacr.org/meeting/aacr-annual-meeting-2021/>. The presentation will also be available under "Events and Presentations" in the Investors section of the Company's website at [www.curis.com](http://www.curis.com).

### **About Curis, Inc.**

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor, ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

SOURCE Curis, Inc.

For further information: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [Stephanie.Ascher@sternir.com](mailto:Stephanie.Ascher@sternir.com)

---

<https://investors.curis.com/2021-03-10-Curis-Announces-Abstract-for-CA-4948-Accepted-for-Presentation-at-the-American-Association-for-Cancer-Research-Annual-Meeting>